Searchable abstracts of presentations at key conferences in endocrinology

ea0056p152 | Neuroendocrinology | ECE2018

Head and neck paragangliomas: genetic mutation and location of the tumors

Recio-Cordova Jose-Maria , Higueruela Cecilia , Caceres Rocio , Garcia-Duque Maria , Gonzalez-Sarmiento Rogelio , Miralles Jose-Manuel , Corrales-Hernandez Juan-Jose , Munoz-Herrera Angel

Introduction: Tumors derived from the paraganglionic system are rare. 90% of them are located on the adrenal gland, and the remaining 10% are extra-adrenal. Within this last group, 85% are located in the abdomen, 12% in the thorax, and 3% in the head and neck region (HNPG). Its proximity to important structures represents a great difficulty for resection. This makes it necessary to refer these patients to reference centers with multidisciplinary teams and specific surgical tra...

ea0056p153 | Neuroendocrinology | ECE2018

Bilateral neck paragangliomas in a patient with a family history and chronic hypoxemia

Higueruela Cecilia , Caceres Rocio , Garcia-Duque Maria , Robles Cristina , Beaulieu Myriam , Iglesias Rosana , Herrerro Ana , Delgado Manuel , Maria Recio-Cordova Jose

Introduction: Tumors derived from the extra-adrenal paraganglionic system are rare (incidence: 0.8/100,000 people/year). In this group, 85% are located in the abdomen, 12% in the thorax, and 3% in the head and neck region (HNPC).Case report: A 46-year-old man, ex-smoker, with a personal history of arterial hypertension, multifactorial secondary polycythemia (obesity, OSA syndrome, hypertrophic cardiomyopathy). Family history: one brother with paraganglio...

ea0056p1093 | Thyroid (non-cancer) | ECE2018

Should tocilizumab be a second-line treatment of active, moderate-to-severe Graves’ Orbitopathy?

Caceres Rocio , Herrero Ana , Recio-Cordova Jose Maria , Sanchez-Marcos Ana , Higueruela Cecilia , Beaulieu Myriam , Iglesias Rosana , Robles Cristina , Garcia-Duque Maria , Corrales-Hernandez Juan Jose

Introduction: GravesÂ’ orbitopathy (GO) is the most common extrathyroidal manifestation of GravesÂ’ disease. The first-line treatment are intravenous corticoids in active moderate-severe GO. Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor which has been approved for the treatment of rheumatoid arthritis and is in its research stage for patients with corticosteroid-refractory GO.Objectives: To assess the experience with to...